Thromboxane A2 (A2, Thromboxane)

An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).

Also Known As:

Networked: 1525 relevant articles (53 outcomes, 158 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Huang, Run-Yue: 6 articles (01/2017 - 04/2011)
2.	Zhang, Jian X: 5 articles (12/2009 - 03/2003)
3.	Dogné, Jean-Michel: 5 articles (09/2009 - 01/2002)
4.	Heemskerk, Johan W M: 4 articles (01/2022 - 04/2003)
5.	Singh, Nirmal: 4 articles (11/2021 - 01/2016)
6.	Butenas, Alec L E: 4 articles (01/2021 - 01/2020)
7.	Copp, Steven W: 4 articles (01/2021 - 01/2020)
8.	Rollins, Korynne S: 4 articles (01/2021 - 01/2020)
9.	Williams, Auni C: 4 articles (01/2021 - 01/2020)
10.	Yu, Ying: 4 articles (12/2020 - 01/2016)

Related Diseases

1.	Thrombosis (Thrombus) 06/30/1989 - "This study suggests that males exposed to LPS may generate more thromboxane A2 than females and thus be at higher risk of developing thrombosis." 11/22/2022 - "Pharmacological Actions of 5-Hydroxyindolin-2 on Modulation of Platelet Functions and Thrombus Formation via Thromboxane A2 Inhibition and cAMP Production." 06/24/2020 - "Platelet activation results in the generation of thromboxane A2 (TxA2), which promotes thrombus formation by further amplifying platelet function, as well as causing vasoconstriction. " 04/01/2019 - "Thromboxane A2 (TXA2) induces platelet aggregation and promotes thrombus formation. " 01/01/2017 - "Ask1 regulates murine platelet granule secretion, thromboxane A2 generation, and thrombus formation."
2.	Ischemia 04/01/1993 - "Although previous studies have already documented the increased release of cardiac thromboxane A2 after ischemia, none have studied the effects of cardiac thromboxane A2 on hemodynamics. " 12/01/1990 - "Our previous studies demonstrated that the bilateral hindlimb ischemia/reperfusion stimulates thromboxane A2 (TXA2) production. " 12/01/1983 - "In this study, the thesis that ischemia of the limb is a significant stimulus to thromboxane A2 synthesis and the generation of a circulating negative inotrope is tested. " 07/01/1996 - "Thromboxane A2 accumulates in the hippocampus after global ischemia and may play a key role in postischemic hypoperfusion. " 04/01/1996 - "Effects of thromboxane A2 synthesis inhibitor (OKY-046) on total liver ischemia in rats."
3.	Myocardial Ischemia (Ischemic Heart Diseases) 12/01/2008 - "Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2?" 08/01/1989 - "Increased Ca2+ influx into platelets induced by thromboxane A2 analog in patients with ischemic heart disease." 11/01/1987 - "Thromboxane A2 (TxA2) production increases significantly during acute myocardial ischemia. " 01/01/1986 - "Potentiation of thromboxane A2 release might contribute to myocardial ischemia associated with platelet activation." 12/01/1985 - "Thromboxane A2 (TxA2) production increases significantly during acute myocardial ischemia. "
4.	Pathologic Constriction (Stenosis) 04/01/1992 - "The aim was to test the hypothesis that thromboxane A2 can cause vasoconstriction of coronary resistance vessels during exercise in hypoperfused regions of myocardium distal to an arterial stenosis. " 12/01/1985 - "This study tested the hypothesis that aggregation of platelets and release of thromboxane A2 at the site of a coronary arterial stenosis may contribute to myocardial ischemia by impairing flow regulation of the distal coronary bed. " 03/01/1998 - "This abnormal behaviour of the stenotic artery has been associated with the occurrence of myocardial ischaemia, and has been thought to be either due to: endothelial dysfunction with reduced release or production of the endothelial derived relaxant factor (EDRF); an increased sympathetic stimulation during exercise; enhanced platelet aggregation with release of thromboxane A2 and serotonin; and/or a passive collapse of the disease-free vessel segment within the stenosis when blood-flow velocity increases during exercise. " 04/01/1992 - "Even during hypoperfusion produced by a flow limiting arterial stenosis, the coronary resistance vessels remain responsive to the vasoconstrictor effect of thromboxane A2. " 11/01/1986 - "These data suggest that the thromboxane A2/PGH2 receptor antagonists, SQ29,548 and SQ28,688, inhibit cyclic reductions in coronary blood flow in this model by preventing the accumulation of platelets at the site of a critical coronary arterial stenosis. "
5.	Inflammation (Inflammations) 01/25/2023 - "In addition, the release of thromboxane A2 from endothelial cells and macrophages stimulates platelets to release microvesicles, which are harbingers of multicellular adhesion and thrombo-inflammation. " 01/01/2016 - "Thromboxane A2 (TXA2) participates in platelet aggregation and tissue inflammation. " 06/15/2003 - "It may exert its beneficial effect not only by acting on platelets, but also by other mechanisms, such as preventing thromboxane A2 (TXA2)-induced vasoconstriction or reducing inflammation. " 09/01/1997 - "These data indicate that thromboxane A2 may contribute to coughing associated with lymphocytic airway inflammation." 01/01/1991 - "Thromboxane A2 is a potent bronchial smooth muscle spasmogen in vitro, and it has been implicated in airway inflammation and in the genesis of bronchial hyperresponsiveness in asthma. "

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Aspirin (Acetylsalicylic Acid)
3.	Prostaglandins
4.	Serotonin (5 Hydroxytryptamine)
5.	Thromboxane Receptors (Thromboxane Receptor)
6.	Thromboxanes
7.	Arachidonic Acid (Vitamin F)
8.	Thromboxane-A Synthase
9.	Leukotriene B4
10.	KW 3635

Related Therapies and Procedures

1.	Secondary Prevention
2.	Blood Component Removal (Apheresis)
3.	Continuous Renal Replacement Therapy
4.	Therapeutics
5.	Intravenous Infusions